IPO - LIPELLA PHARMACEUTICALS INC.

Form Type: S-3

Filing Date: 2025-01-07

Corporate Action: Ipo

Type: New

Accession Number: 000175392625000059

Filing Summary: Lipella Pharmaceuticals Inc. filed a registration statement on Form S-3 with the U.S. Securities and Exchange Commission on January 7, 2025, to register a total of 1,372,408 shares of common stock. This includes 972,151 shares from the conversion of Series B Preferred Stock, 303,041 shares from the conversion of Series C Preferred Stock, and 97,216 shares from the exercise of Placement Agent Warrants. The registration allows these shares to be offered and sold by Selling Stockholders. The shares will be sold through public or private transactions, with the offering designed to occur from time to time after the effective date. Notably, the common stock is listed on the Nasdaq Capital Market under the symbol 'LIPO'. The company is classified as an emerging growth and smaller reporting company, allowing it to adhere to reduced reporting obligations. The offering is part of a private placement financing strategy and follows a recent completion of a reverse stock split on November 7, 2024, consolidating every eight shares into one. The anticipated use of proceeds is for working capital and corporate purposes, though the company will not receive proceeds from resale of the shares by Selling Stockholders.

Document Link: View Document